Your browser doesn't support javascript.
loading
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma.
Vegliante, Maria Carmela; Mazzara, Saveria; Zaccaria, Gian Maria; De Summa, Simona; Esposito, Flavia; Melle, Federica; Motta, Giovanna; Sapienza, Maria Rosaria; Opinto, Giuseppina; Volpe, Giacomo; Bucci, Antonella; Gargano, Grazia; Enjuanes, Anna; Tabanelli, Valentina; Fiori, Stefano; Minoia, Carla; Clemente, Felice; Negri, Antonio; Gulino, Alessandro; Morello, Gaia; Scattone, Anna; Zito, Alfredo F; Tommasi, Stefania; Agostinelli, Claudio; Vitolo, Umberto; Chiappella, Annalisa; Barbui, Anna Maria; Derenzini, Enrico; Zinzani, Pier Luigi; Casadei, Beatrice; Rivas-Delgado, Alfredo; López-Guillermo, Armando; Campo, Elias; Moschetta, Antonio; Guarini, Attilio; Pileri, Stefano A; Ciavarella, Sabino.
Affiliation
  • Vegliante MC; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Mazzara S; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Zaccaria GM; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • De Summa S; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Esposito F; Department of Mathematics, University of Bari Aldo Moro, Bari, Italy.
  • Melle F; INDAM-GNCS Research Group, Rome, Italy.
  • Motta G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Sapienza MR; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Opinto G; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Volpe G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Bucci A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Gargano G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Enjuanes A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Tabanelli V; INDAM-GNCS Research Group, Rome, Italy.
  • Fiori S; Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain.
  • Minoia C; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Clemente F; Division of Hematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Negri A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Gulino A; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Morello G; Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Scattone A; Cogentech srl Società Benefit, FIRC Institute of Molecular Oncology (IFOM), Milan, Italy.
  • Zito AF; Department of Health Sciences, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy.
  • Tommasi S; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Agostinelli C; Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Vitolo U; Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
  • Chiappella A; Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Barbui AM; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Derenzini E; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Zinzani PL; Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Casadei B; Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Rivas-Delgado A; Onco-Hematology Division, European Institute of Oncology IRCCS, Milan, Italy.
  • López-Guillermo A; Department of Health Sciences, University of Milan, Milan, Italy.
  • Campo E; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Moschetta A; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Guarini A; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Pileri SA; Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Ciavarella S; CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain.
Hematol Oncol ; 40(5): 864-875, 2022 Dec.
Article in En | MEDLINE | ID: mdl-35850118
ABSTRACT
The role of macrophages (Mo) and their prognostic impact in diffuse large B-cell lymphomas (DLBCL) remain controversial. By regulating the lipid metabolism, Liver-X-Receptors (LXRs) control Mo polarization/inflammatory response, and their pharmacological modulation is under clinical investigation to treat human cancers, including lymphomas. Herein, we surveyed the role of LXRs in DLBCL for prognostic purposes. Comparing bulk tumors with purified malignant and normal B-cells, we found an intriguing association of NR1H3, encoding for the LXR-α isoform, with the tumor microenvironment (TME). CIBERSORTx-based purification on large DLBCL datasets revealed a high expression of the receptor transcript in M1-like pro-inflammatory Mo. By determining an expression cut-off of NR1H3, we used digital measurement to validate its prognostic capacity on two large independent on-trial and real-world cohorts. Independently of classical prognosticators, NR1H3high patients displayed longer survival compared with NR1H3low cases and a high-resolution Mo GEP dissection suggested a remarkable transcriptional divergence between subgroups. Overall, our findings indicate NR1H3 as a Mo-related biomarker identifying patients at higher risk and prompt future preclinical studies investigating its mouldability for therapeutic purposes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Hematol Oncol Year: 2022 Document type: Article Affiliation country: Italia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Hematol Oncol Year: 2022 Document type: Article Affiliation country: Italia